DSIP Research Guide Ireland

Overview

DSIP (Delta Sleep-Inducing Peptide) is a nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) first isolated from the cerebral venous blood of rabbits kept in an induced sleep state. The foundational discovery was published in 1977 by Schoenenberger GA and Monnier M in the Proceedings of the National Academy of Sciences, describing a peptide associated with delta-wave (slow-wave) EEG activity — the basis for its name. Early research through the late 1970s and 1980s explored possible roles for DSIP in sleep regulation, circadian rhythm, and modulation of the stress/HPA axis. It is important to be upfront that DSIP has a genuinely mixed and inconsistent replication history. Several follow-up human studies conducted through the 1980s and 1990s failed to consistently replicate the sleep-promoting effects reported in early work, and no receptor or definitive mechanism of action was ever conclusively identified for DSIP — unlike, for example, ghrelin-receptor peptides with a clear binding target. By the 1990s and 2000s, scientific interest in DSIP declined markedly due to these inconsistent findings and the inability to establish a clear mechanism, and some researchers have questioned whether DSIP functions as a discrete "sleep hormone" at all, versus a more general stress-modulating or neuromodulatory peptide. This guide presents that uncertainty honestly rather than promoting DSIP as an established sleep aid. This guide is for educational and research purposes only. Not medical advice.

Clinical & Research Status

Evidence Type	Status
Human RCT	✔
Observational	✔
Animal Studies	✔
In Vitro	✗
Regulatory Approval	✗

Small human studies exist, but they are older, limited in scale, and have produced inconsistent results across independent replications. In vitro mechanistic work is minimal to absent given that no confirmed receptor target has been established. No regulatory approval exists for DSIP for any indication.

Mechanism of Action

Unlike well-characterised secretagogue or receptor-targeted peptides, DSIP's mechanism of action was never conclusively established. Researchers in the years following its discovery proposed several hypothesised interactions — including modulation of GABAergic signalling, involvement in HPA-axis regulation (particularly cortisol modulation), and possible interplay with opioid or other neuromodulatory systems — but none of these pathways has been confirmed as the definitive mode of action. This absence of a clear, reproducible mechanism is itself one of the most significant limitations of the DSIP literature. Without an identified receptor or binding target, it has been difficult for researchers to design targeted follow-up studies or to explain why early findings were not consistently replicated in later, better-controlled trials. Any discussion of DSIP's mechanism should therefore be understood as hypothesis-level rather than established pharmacology.

Research Areas & Reported Effects

Sleep Architecture & Delta-Wave Research

The original rabbit studies by Schoenenberger and Monnier reported induction of delta-wave (slow-wave) EEG activity following administration of the isolated peptide, giving DSIP its name and forming the basis for early interest in it as a potential sleep-regulating compound.

Replication Challenges & Inconsistent Findings

This is a central and necessary section of the DSIP research record: numerous follow-up studies in the 1980s and 1990s attempting to replicate the early sleep-promoting findings in humans produced inconsistent or null results. Effect sizes varied considerably between studies, some found no measurable improvement in sleep quality or architecture, and the lack of a confirmed mechanism made it difficult to reconcile these discrepancies. This replication difficulty is a primary reason scientific interest in DSIP declined substantially by the 1990s–2000s.

Stress and HPA-Axis Modulation Research

Some research explored DSIP's potential role in modulating the hypothalamic-pituitary-adrenal (HPA) axis and cortisol secretion, framing it as a possible stress-modulating peptide rather than a sleep-specific one. These findings remain exploratory and have not been robustly confirmed in well-controlled human trials.

Circadian Rhythm Research

A smaller body of work examined whether DSIP administration influenced circadian rhythm markers. As with the sleep-architecture research, results across studies were variable, and no consistent circadian effect has been firmly established in the literature.

Research Data Summary

Study / Model	Reported Effect
Schoenenberger GA, Monnier M (1977) — Rabbit model	Isolation of a peptide from cerebral venous blood associated with induction of delta-wave (slow-wave) sleep activity.
Subsequent small human trials (1980s–1990s)	Variable and inconsistent sleep-quality outcomes; several studies failed to replicate the original delta-wave findings.
Later controlled human trials	Inconsistent or null findings reported by multiple independent groups, contributing to declining research interest.

Stack Combinations Studied

• DSIP + GABAergic-modulating compounds → Research rationale: Explored on the hypothesis that DSIP may interact with GABAergic signalling pathways implicated in sleep regulation, though this mechanism remains unconfirmed.

⚠️ Stack combinations listed for research reference only. Not safety or efficacy guidance.

Research Protocol Reference

experimental research protocols only — not dosing recommendations.

Protocol	Dose (experimental model only)	Duration (experimental model only)	Frequency (experimental model only)	Research Context
Low-Range Historical Reference	0.1 mg	Single-dose historical study designs	Once, at night (per historical study protocol)	Early delta-wave / EEG observation studies.
Standard Historical Reference	0.15–0.2 mg	Days to short weeks (per historical trial design)	Nightly (per historical study protocol)	Small human sleep-quality studies, variable results.
Upper Historical Reference	0.3 mg	Short-term historical study windows	Nightly (per historical study protocol)	HPA-axis and stress-modulation exploratory research.

These figures reflect the low, microgram-to-low-milligram range reported in older historical human studies and are presented purely as historical research reference, not as a recommendation — comprehensive modern dosing data does not exist for DSIP.

Observed Side Effects in Research

• Transient dizziness (reported in some older study subjects)
• Mild headache (infrequent, reported in limited historical literature)

Modern, comprehensive safety data for DSIP is lacking given how old and limited the existing study base is. The available literature is drawn largely from small studies conducted decades ago, and no large-scale modern safety trial has been conducted to confirm or update this picture.

Compound Data

CAS Number

62568-57-4

Molecular Formula

C₃₃H₄₉N₁₃O₁₅S

Molecular Weight

Approximately 847.86 g/mol

Half-Life

Short, approximately a few minutes in circulation (rapidly degraded) — cited in the literature as a limitation of proposed therapeutic use

Synonyms

Delta Sleep-Inducing Peptide, DSIP

Research Classification

Nonapeptide, Historical Sleep/Neuromodulatory Research Compound

Scientific References

• [Schoenenberger GA, Monnier M. 1977] — Characterization of a delta-electroencephalogram(-sleep)-inducing peptide. — Proceedings of the National Academy of Sciences — [Animal / Discovery]
• [Graf M, Kastin AJ. 1986] — Delta-sleep-inducing peptide (DSIP): an update. — Peptides — [Review, discusses replication issues]

This compliance check is automated and does not constitute legal advice. No Nonsense Fitness recommends independent legal review for all published content.